Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial

Highlight

– Daily low-dose aspirin (160 mg) significantly reduces the 3-year colorectal cancer recurrence rate in patients harboring somatic PIK3CA hotspot mutations (exon 9 or 20).
– Aspirin shows a similar beneficial effect on disease recurrence in patients with additional moderate- to high-impact somatic variants in the PI3K pathway genes PIK3CA, PIK3R1, or PTEN.
– Disease-free survival was numerically improved with aspirin, though not always statistically significant depending on subgroup.
– Safety profile shows a modest increase in severe adverse events with aspirin use relative to placebo.

Study Background and Disease Burden